

## Food and Drug Administration, HHS

## § 314.3

- 314.430 Availability for public disclosure of data and information in an application or abbreviated application.
- 314.440 Addresses for applications and abbreviated applications.
- 314.445 Guidance documents.

### Subpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses

- 314.500 Scope.
- 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
- 314.520 Approval with restrictions to assure safe use.
- 314.530 Withdrawal procedures.
- 314.540 Postmarketing safety reporting.
- 314.550 Promotional materials.
- 314.560 Termination of requirements.

### Subpart I—Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible

- 314.600 Scope.
- 314.610 Approval based on evidence of effectiveness from studies in animals.
- 314.620 Withdrawal procedures.
- 314.630 Postmarketing safety reporting.
- 314.640 Promotional materials.
- 314.650 Termination of requirements.

AUTHORITY: 21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 356a, 356b, 356c, 371, 374, 379e.

SOURCE: 50 FR 7493, Feb. 22, 1985, unless otherwise noted.

EDITORIAL NOTE: Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004.

## Subpart A—General Provisions

### § 314.1 Scope of this part.

(a) This part sets forth procedures and requirements for the submission to, and the review by, the Food and Drug Administration of applications and abbreviated applications to market a new drug under section 505 of the Federal Food, Drug, and Cosmetic Act, as well as amendments, supplements, and postmarketing reports to them.

(b) This part does not apply to drug products subject to licensing by FDA under the Public Health Service Act (58 Stat. 632 as amended (42 U.S.C. 201 *et seq.*)) and subchapter F of chapter I of title 21 of the Code of Federal Regulations.

(c) References in this part to regulations in the Code of Federal Regula-

tions are to chapter I of title 21, unless otherwise noted.

[50 FR 7493, Feb. 22, 1985, as amended at 57 FR 17981, Apr. 28, 1992; 64 FR 401, Jan. 5, 1999]

### § 314.2 Purpose.

The purpose of this part is to establish an efficient and thorough drug review process in order to: (a) Facilitate the approval of drugs shown to be safe and effective; and (b) ensure the disapproval of drugs not shown to be safe and effective. These regulations are also intended to establish an effective system for FDA's surveillance of marketed drugs. These regulations shall be construed in light of these objectives.

### § 314.3 Definitions.

(a) The definitions and interpretations contained in section 201 of the act apply to those terms when used in this part.

(b) The following definitions of terms apply to this part:

*Abbreviated application* means the application described under § 314.94, including all amendments and supplements to the application. "Abbreviated application" applies to both an abbreviated new drug application and an abbreviated antibiotic application.

*Act* means the Federal Food, Drug, and Cosmetic Act (sections 201–901 (21 U.S.C. 301–392)).

*Applicant* means any person who submits an application or abbreviated application or an amendment or supplement to them under this part to obtain FDA approval of a new drug or an antibiotic drug and any person who owns an approved application or abbreviated application.

*Application* means the application described under § 314.50, including all amendments and supplements to the application.

*505(b)(2) Application* means an application submitted under section 505(b)(1) of the act for a drug for which the investigations described in section 505(b)(1)(A) of the act and relied upon by the applicant for approval of the application were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.